Furthermore, we find that upregulation of GCNT1 can alter the glycome of prostate cancer cells to increase levels of core 2 O-glycans and upregulate expression of sLeX, and can impact oncogenic gene expression patterns. This evidence concerns the gene GCNT1 and prostate carcinoma.